Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Puma Biotechnology, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
PBYI
Nasdaq
2836
www.pumabiotechnology.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Puma Biotechnology, Inc.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Feb 5th, 2025 10:05 pm
US Penny Stocks To Watch In January 2025
- Jan 29th, 2025 5:05 pm
Is Now The Time To Put Puma Biotechnology (NASDAQ:PBYI) On Your Watchlist?
- Jan 17th, 2025 11:08 am
Best Value Stocks to Buy for January 6th
- Jan 6th, 2025 7:59 am
Is Puma Biotechnology (PBYI) Stock Undervalued Right Now?
- Jan 1st, 2025 2:40 pm
US Penny Stocks With Promise: 3 Picks Under $200M Market Cap
- Dec 27th, 2024 8:05 pm
Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why
- Dec 27th, 2024 3:10 pm
Is Bristol Myers Squibb (BMY) Stock Undervalued Right Now?
- Dec 26th, 2024 2:40 pm
Best Momentum Stocks to Buy for December 24th
- Dec 24th, 2024 3:15 pm
Best Value Stocks to Buy for December 24th
- Dec 24th, 2024 8:12 am
With 49% stake, Puma Biotechnology, Inc. (NASDAQ:PBYI) seems to have captured institutional investors' interest
- Dec 23rd, 2024 6:50 pm
Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation
- Dec 23rd, 2024 2:01 pm
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock?
- Dec 18th, 2024 2:40 pm
Should Value Investors Buy Puma Biotechnology (PBYI) Stock?
- Nov 28th, 2024 2:40 pm
Discovering Promising US Penny Stocks In November 2024
- Nov 26th, 2024 5:09 pm
PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer
- Nov 21st, 2024 4:11 pm
Puma commences Phase II trial of alisertib for breast cancer treatment
- Nov 21st, 2024 10:38 am
Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
- Nov 20th, 2024 1:57 pm
We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative
- Nov 14th, 2024 11:56 am
Puma Biotechnology Third Quarter 2024 Earnings: Beats Expectations
- Nov 9th, 2024 2:02 pm
Scroll